Literature DB >> 26339041

Administration of unfractionated heparin with prolonged fasting could reduce physiological 18F-fluorodeoxyglucose uptake in the heart.

Atsuro Masuda1, Masanao Naya2, Osamu Manabe1, Keiichi Magota3, Keiichiro Yoshinaga1, Hiroyuki Tsutsui4, Nagara Tamaki1.   

Abstract

BACKGROUND: The physiological uptake of 18F-fluorodeoxyglucose (FDG) in the heart often interferes with the accurate diagnosis of inflammatory cardiac diseases (CDs). Unfractionated heparin (UFH) administration may suppress its uptake through the alteration of myocardial metabolism.
PURPOSE: To clarify the effectiveness of UFH administration to suppress the physiological FDG uptake in the heart.
MATERIAL AND METHODS: The physiological FDG uptake in the heart was compared among 178 patients who fasted less than 18 h, 37 patients who fasted more than 18 h, and 64 patients who fasted more than 18 h and were administered UFH (UFH-CD group) prior to FDG PET/CT. Free fatty acid (FFA), triglyceride, insulin, and blood glucose levels were measured after UFH administration. Myocardial FDG uptake was evaluated by visual assessment and on the basis of maximum standardized uptake value (SUVmax).
RESULTS: In the UFH-CD group, the FFA level increased 15 min after UFH administration (P < 0.01). Blood glucose and insulin levels remained unchanged (P = NS). FDG physiological uptake was observed in 69% of the patients who fasted less than 18 h, 38% of the patients fasted more than 18 h, and 22% of the UFH-CD group (P < 0.01 for trend). SUVmax decreased in the UFH-CD group compared with the patients who fasted less than 18 h (P < 0.01) and the patients who fasted more than 18 h (P = 0.029).
CONCLUSION: UFH administration and fasting more than 18 h could effectively suppress FDG physiological uptake in the heart and can be a useful method of detecting inflammatory CDs and tumors. © The Foundation Acta Radiologica 2015.

Entities:  

Keywords:  Cardiac; PET; inflammation; physiological FDG uptake

Mesh:

Substances:

Year:  2015        PMID: 26339041     DOI: 10.1177/0284185115600916

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  10 in total

1.  Characterization of a highly effective preparation for suppression of myocardial glucose utilization.

Authors:  Sophia R Larson; Justin A Pieper; Edward A Hulten; Edward P Ficaro; James R Corbett; Venkatesh L Murthy; Richard L Weinberg
Journal:  J Nucl Cardiol       Date:  2019-06-24       Impact factor: 5.952

2.  Joint SNMMI-ASNC expert consensus document on the role of 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Cardiol       Date:  2017-10       Impact factor: 5.952

3.  Continuing evolution in preparation protocols for 18FDG PET assessment of inflammatory or malignant myocardial disease.

Authors:  John P Bois; Panithaya Chareonthaitawee
Journal:  J Nucl Cardiol       Date:  2016-03-25       Impact factor: 5.952

4.  Volume-based glucose metabolic analysis of FDG PET/CT: The optimum threshold and conditions to suppress physiological myocardial uptake.

Authors:  Osamu Manabe; Markus Kroenke; Tadao Aikawa; Atsuto Murayama; Masanao Naya; Atsuro Masuda; Noriko Oyama-Manabe; Kenji Hirata; Shiro Watanabe; Tohru Shiga; Chietsugu Katoh; Nagara Tamaki
Journal:  J Nucl Cardiol       Date:  2017-12-14       Impact factor: 5.952

5.  Does simplified quantitative analysis of 18F-FDG PET in cardiac inflammatory disease work?

Authors:  R Nkoulou; H Zaidi
Journal:  J Nucl Cardiol       Date:  2018-01-17       Impact factor: 5.952

6.  Joint SNMMI-ASNC Expert Consensus Document on the Role of 18F-FDG PET/CT in Cardiac Sarcoid Detection and Therapy Monitoring.

Authors:  Panithaya Chareonthaitawee; Rob S Beanlands; Wengen Chen; Sharmila Dorbala; Edward J Miller; Venkatesh L Murthy; David H Birnie; Edward S Chen; Leslie T Cooper; Roderick H Tung; Eric S White; Salvador Borges-Neto; Marcelo F Di Carli; Robert J Gropler; Terrence D Ruddy; Thomas H Schindler; Ron Blankstein
Journal:  J Nucl Med       Date:  2017-08       Impact factor: 10.057

7.  Hot spot imaging in cardiovascular diseases: an information statement from SNMMI, ASNC, and EANM.

Authors:  Brett W Sperry; Timothy M Bateman; Esma A Akin; Paco E Bravo; Wengen Chen; Vasken Dilsizian; Fabien Hyafil; Yiu Ming Khor; Robert J H Miller; Riemer H J A Slart; Piotr Slomka; Hein Verberne; Edward J Miller; Chi Liu
Journal:  J Nucl Cardiol       Date:  2022-07-21       Impact factor: 3.872

Review 8.  Current State and Future Directions of Multimodality Imaging in Cardiac Sarcoidosis.

Authors:  Alison L Wand; Jonathan Chrispin; Elie Saad; Monica Mukherjee; Allison G Hays; Nisha A Gilotra
Journal:  Front Cardiovasc Med       Date:  2022-01-27

9.  Fluorine-18 fluorodeoxyglucose positron emission tomography for cardiac sarcoidosis-is it time to consider a new radiotracer?

Authors:  Georgios Christopoulos; Panithaya Chareonthaitawee
Journal:  EJNMMI Res       Date:  2017-08-29       Impact factor: 3.138

Review 10.  PET Imaging in Cardiac Sarcoidosis: A Narrative Review with Focus on Novel PET Tracers.

Authors:  Petar Saric; Kathleen A Young; Martin Rodriguez-Porcel; Panithaya Chareonthaitawee
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.